Clinical application of sirolimus in renal transplantation: an update

被引:43
作者
Chueh, SCJ
Kahan, BD
机构
[1] Univ Texas, Sch Med, Dept Surg, Div Organ Transplantat, Houston, TX 77030 USA
[2] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Urol, Taipei 10764, Taiwan
[3] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
关键词
cyclosporine; immunosuppression; renal transplantation; sirolimus; tacrolimus;
D O I
10.1111/j.1432-2277.2004.00039.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
In addition to an analysis of the final results of phase I/II and phase III clinical trials of sirolimus (SRL), this review focuses on the recent results of several studies in renal transplantation, which include diverse combinations of SRL with other immunosuppressive agents. While SRL was initially introduced as an adjunctive agent to calcineurin inhibitors, it is now serving as the base for therapies that spare or avoid these nephrotoxic drugs. However, to optimize the use of SRL as base therapy, further work is necessary to determine target concentrations, requirement for concomitant steroids and/or nucleoside synthesis blockers, and countermeasure therapy to overcome the drug's adverse effects.
引用
收藏
页码:261 / 277
页数:17
相关论文
共 95 条
  • [1] AMM JM, 2003, AM J TRANSPLANT, V3, P211
  • [2] [Anonymous], AM J TRANSPLANTAT S5
  • [3] [Anonymous], AM J TRANSPLANTAT S5
  • [4] [Anonymous], AM J TRANSPLANTAT S5
  • [5] [Anonymous], AM J TRANSPLANTAT S5
  • [6] [Anonymous], AM J TRANSPLANTAT S5
  • [7] [Anonymous], AM J TRANSPLANTAT S5
  • [8] [Anonymous], AM J TRANSPLANTAT S5
  • [9] [Anonymous], AM J TRANSPLANTAT S5
  • [10] [Anonymous], AM J TRANSPLANTAT S5